Investigation ongoing – statement to be updated as more information is available FDA alerts patients and health care professionals to Sandoz’s losartan potassium and hydrochlorothiazide recall of one lot due to NDEA Update [11/9/2018] FDA is alerting patients and health care … Continue reading →